%0 Journal Article
%A Bernhardt, Alexander Maximilian
%A Oeller, Marc
%A Friedrich, Isabel
%A Kocakavuk, Emre
%A Nachman, Eliana
%A Peikert, Kevin
%A Roderigo, Malte
%A Rossmann, Andreas
%A Schröter, Tabea
%A Wilhelm, Lea Olivia
%A Prell, Tino
%A van Riesen, Christoph
%A Nieweler, Johanna
%A Katzdobler, Sabrina
%A Weiler, Markus
%A Jacobi, Heike
%A Warnecke, Tobias
%A Claus, Inga
%A Palleis, Carla
%A Breimann, Stephan
%A Falkenburger, Björn
%A Brandt, Moritz
%A Hermann, Andreas
%A Rumpf, Jost-Julian
%A Claßen, Joseph
%A Höglinger, Günter
%A Gandor, Florin
%A Levin, Johannes
%A Giese, Armin
%A Janzen, Annette
%A Oertel, Wolfgang Hermann
%T Risk willingness in multiple system atrophy and Parkinson's disease understanding patient preferences.
%J npj Parkinson's Disease
%V 10
%N 1
%@ 2373-8057
%C London [u.a.]
%I Nature Publ. Group
%M DZNE-2024-01039
%P 158
%D 2024
%X Disease-modifying therapeutics in the α-synucleinopathies multiple system atrophy (MSA) and Parkinson's Disease (PD) are in early phases of clinical testing. Involving patients' preferences including therapy-associated risk willingness in initial stages of therapy development has been increasingly pursued in regulatory approval processes. In our study with 49 MSA and 38 PD patients, therapy-associated risk willingness was quantified using validated standard gamble scenarios for varying severities of potential drug or surgical side effects. Demonstrating a non-gaussian distribution, risk willingness varied markedly within, and between groups. MSA patients accepted a median 1
%F PUB:(DE-HGF)16
%9 Journal Article
%2 pmc:PMC11327309
%$ pmid:39147806
%R 10.1038/s41531-024-00764-5
%U https://pub.dzne.de/record/271338